Silvan Tuerkcan's Stock Ratings

JMP Securities Analyst

Silvan Tuerkcan is an analyst at JMP Securities. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/17/2024

Overall Average Return

0.16%

Smart Score

54%

Overall Average Return Percentile

36th

Number of Ratings

102
Buy NowGet Alert
05/13/2024VORBuy Now
Vor Biopharma
$1.81563.02% → $12ReiteratesMarket Outperform → Market OutperformGet Alert
05/10/2024MGNXBuy Now
Macrogenics
$4.33269.52%$22 → $16MaintainsMarket OutperformGet Alert
05/09/2024CRSPBuy Now
CRISPR Therapeutics
$54.9956.39% → $86ReiteratesMarket Outperform → Market OutperformGet Alert
05/06/2024RLAYBuy Now
Relay Therapeutics
$7.02241.88% → $24ReiteratesMarket Outperform → Market OutperformGet Alert
04/30/2024TERNBuy Now
Terns Pharma
$6.25140% → $15ReiteratesMarket Outperform → Market OutperformGet Alert
04/25/2024ACRVBuy Now
Acrivon Therapeutics
$8.5598.83%$14 → $17MaintainsMarket OutperformGet Alert
04/22/2024BNTCBuy Now
Benitec Biopharma
$10.1357.98%$10 → $16MaintainsMarket OutperformGet Alert
04/15/2024NTBLBuy Now
Notable Labs
$1.04765.3% → $9ReiteratesMarket Outperform → Market OutperformGet Alert
04/10/2024EXELBuy Now
Exelixis
$21.0128.51% → $27ReiteratesMarket Outperform → Market OutperformGet Alert
04/04/2024MGNXBuy Now
Macrogenics
$4.33——Reiterates → Market OutperformGet Alert
04/01/2024ACRVBuy Now
Acrivon Therapeutics
$8.5563.74% → $14ReiteratesMarket Outperform → Market OutperformGet Alert
03/22/2024VORBuy Now
Vor Biopharma
$1.81563.02% → $12ReiteratesMarket Outperform → Market OutperformGet Alert
03/20/2024TSHABuy Now
Taysha Gene Therapies
$3.0066.94% → $5ReiteratesMarket Outperform → Market OutperformGet Alert
03/18/2024TERNBuy Now
Terns Pharma
$6.25140%$17 → $15MaintainsOutperformGet Alert
03/11/2024MGNXBuy Now
Macrogenics
$4.33408.08%$16 → $22MaintainsOutperformGet Alert
03/07/2024ELEVBuy Now
Elevation Oncology
$3.6193.91% → $7ReiteratesMarket Outperform → Market OutperformGet Alert
03/05/2024MNDYBuy Now
Monday.Com
$227.5923.03%$240 → $280MaintainsBuyGet Alert
03/01/2024ELEVBuy Now
Elevation Oncology
$3.6193.91% → $7Initiates → Market OutperformGet Alert
03/01/2024ACRVBuy Now
Acrivon Therapeutics
$8.5563.74% → $14Initiates → Market OutperformGet Alert
02/15/2024BNTCBuy Now
Benitec Biopharma
$10.13-1.26%$8 → $10MaintainsMarket OutperformGet Alert
01/24/2024MGNXBuy Now
Macrogenics
$4.33269.52%$10 → $16MaintainsMarket OutperformGet Alert
01/24/2024BNTCBuy Now
Benitec Biopharma
$10.13-21.01%$6 → $8MaintainsMarket OutperformGet Alert
12/19/2023NTBLBuy Now
Notable Labs
$1.04765.3%$13 → $9MaintainsMarket OutperformGet Alert
12/14/2023EXELBuy Now
Exelixis
$21.0128.51% → $27ReiteratesMarket Outperform → Market OutperformGet Alert
12/11/2023CRSPBuy Now
CRISPR Therapeutics
$54.9945.48%$74 → $80MaintainsMarket OutperformGet Alert
12/05/2023TERNBuy Now
Terns Pharma
$6.25172% → $17ReiteratesMarket Outperform → Market OutperformGet Alert
12/05/2023CRSPBuy Now
CRISPR Therapeutics
$54.9934.57% → $74ReiteratesMarket Outperform → Market OutperformGet Alert
11/13/2023EXELBuy Now
Exelixis
$21.0128.51% → $27ReiteratesMarket Outperform → Market OutperformGet Alert
11/01/2023CLLSBuy Now
Cellectis
$2.91106.19%$6 → $6ReiteratesMarket Outperform → Market OutperformGet Alert
10/23/2023GBIOBuy Now
Generation Bio
$3.53——DowngradeMarket Outperform → Market PerformGet Alert

Recent Analyst Stock Rating News

The Analyst Landscape: 12 Takes On Monday.Com
Key Takeaways From Relay Therapeutics Analyst Ratings
The Analyst Verdict: Exelixis In The Eyes Of 5 Experts
11 Analysts Assess Taysha Gene Therapies: What You Need To Know
Where Monday.Com Stands With Analysts
What Analysts Are Saying About Exelixis Stock
Evaluating Taysha Gene Therapies: Insights From 7 Financial Analysts
Look Out For These 6 Stocks As Analysts Predicts Major Gains, One Up To 82%
Investment analysts have revised their price targets upwards for six major stocks this week, with one company expected to see an 82% surge. The revised targets include four U.S.-listed companies, with the most significant upgrade forecasted for a biopharmaceutical firm.
The Latest Analyst Ratings For Macrogenics
12 Analysts Have This To Say About Monday.Com
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free